Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib and midazolam pharmacokinetic study in advanced gastrointestinal stromal tumor
NL-OMON60179Phase 1Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ripretinib and midazolam in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Started Jul 2024; status: active, not recruiting.
02
Drugs
ripretinibmidazolam
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON60179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60179.